2024-10-24-上交所-健康元药业集团股份有限公司2024年第三季度报告（英文版）_13页_328kb

Joincare Pharmaceutical 2024 Third Quarterly Report Summary

Financial Performance Overview

• Revenues for the first nine months of 2024 totaled RMB 11,898,828,905.02, representing a year-over-year decrease of 6.80% compared to RMB 12,651,257,386.44 in 2023.
• Net profit attributable to shareholders of the listed company was RMB 1,111,560,063.92 for the same period, showing a modest year-over-year increase of 2.58%.
• Net profit from continuing operations was RMB 2,433,696,525.07, up from RMB 2,244,795,311.84 in 2023.
• Basic earnings per share were RMB 0.59, an increase of 4.63% YoY.

Key Revenue Drivers

• Chemical pharmaceuticals segment revenue decreased by 10.55% YoY to RMB 5,879 million, with specific products showing mixed results:
  • Gonadotropic hormones revenue increased 5.46% to RMB 2,308 million.
  • Gastroenterology revenue declined 18.66% to RMB 1,854 million.
  • Respiratory formulation revenue dropped 28.18% to RMB 799 million.
  • Psychiatry revenue increased 3.11% to RMB 443 million.
  • APIs and intermediates revenue fell 2.83% to RMB 3,857 million.
• Diagnostic reagents and health care products demonstrated strong growth, with revenues up 21.03% and 97.67% respectively.

Operating Analysis

• Gross profit margin improved due to effective cost management.
• Operating costs increased by 9.31% YoY to RMB 9,121,682,123.61.
• Key factors included higher advance recognition and foreign exchange effects.
• Operating profit reached RMB 2,832,383,097.69, an increase of 5.31% YoY.

Financial Health Indicators

• Net assets attributable to shareholders rose to RMB 14,487,774,610.56, up 5.32% YoY.
• Net cash flow from operating activities increased 6.25% to RMB 2,613,605,501.06.
• Balance sheet shows total assets down by 0.51%, mainly due to outstanding payments and employee stock options.

Shareholder Information

• Top shareholders include Shenzhen Baiyeyuan Investment Co., Ltd. with 47.79% stake, and Hong Kong Securities Clearing Company Limited.
• No significant changes in shareholder structure during the quarter, with no acted-in-concert relationships reported.

Non-Recurring Items and Notes

• Extraordinary gains and losses were partially disclosed, including government grants and fair value changes.
• Partial audit indicates unaudited statements as per standard practices.

This summary highlights key trends in financial performance, revenue segmentation, and market context for the 2024 third quarter, with net profit growth despite revenue decline indicating improved operational efficiency.